ABOUT
US BIOLOGIC Delivers Disease Prevention®.
US BIOLOGIC develops groundbreaking orally delivered vaccines, changing global disease prevention and allowing safe, effective, and cost-efficient delivery of preventative interventions to wildlife, companion animals, food animals, and humans.
We work with world-renowned experts, placing their proven technologies into our oral-delivery platform. We then commercialize those new products by providing necessary funding, regulatory support, manufacturing, and distribution expertise.
LEADERSHIP
Executive & Science Leadership
Roan earned his BS in Mechanical Engineering from Tennessee Technological University and an MBA from the University of Memphis. He has extensive experience in strategy, operations, and new product innovation, bridging the gap between product development, operations, and commercialization. Before joining US Biologic, Roan led R&D for Smith & Nephew’s orthopedic $650M hip franchise and lead cross functional teams to ideate, develop, and launch multiple large-scale orthopedic hip and knee platforms. He has led large-scale regulatory initiatives, global product data standardization, and change management programs. Early in his career, he gained deep expertise in lean product development and manufacturing at Toyota, experience that continues to shape his approach to operational excellence.
Dr. Brooke received a Master of Public Health from the Vrije Universiteit Amsterdam and a PhD in Clinical Epidemiology from Utrecht University. He has worked with National and International public health departments in Europe and the U.S. on seroprevalence, notifiable infectious diseases, human dose-response models, and geospatial trends of zoonotic infection pressure combining clinical trial data, real-world data, and big data. He then worked in pharmacogenomics survivorship at St. Jude Children's Research Hospital using whole-genome sequencing to develop analytics pipelines. Recently, he transitioned into the medical-device industry working for Smith&Nephew where he planned and executed the creation of an Artificial Intelligence Center of Excellence to help the 150-year-old company transition into the digital age. Dr. Brooke has advised several companies with regard to their digital health strategy and enjoys making corporate vision into reality. He has 19 publications, three patents, and two invention disclosures.
Bryan is a results-driven, award-winning state government affairs and communications leader with extensive experience influencing legislative and regulatory environments to align with strategic business goals. He holds a BA in Communications from the University of Oregon and an MBA in Marketing from Saint Leo University. Before joining US Biologic, Bryan served as Executive Vice President of Government Relations for Acreage Holdings, where he led legislative efforts across eight states, managed a $1.25M budget, secured a $60M market opportunity, and saved $10M through tax reform. Before joining Acreage, Bryan successfully directed a $300K rebranding initiative at Mid-America Baptist Theological Seminary, enhancing the institution's public image and engagement. Bryan also spent 13 years in increasing leadership roles at Pfizer, where he was instrumental in passing key healthcare legislation, protecting market access, and developing policies and resources to inform public policy.
Board of Directors
Senior Advisors
Mr. Oberholtzer received his B.B.A. from George Washington University. Mr. Oberholtzer is the co-founder of a multi-billion dollar registered private markets investment firm, focused on established and growth companies. He has 38 years of investment advisory experience in alternative investments. He actively manages private investments across industries sectors and product stages, and served on more the board of more than a dozen company boards. As an active investor, Mr. Oberholtzer provides operating and strategic guidance as a board member or observer. Prior to WP Global, he was a Director of WestAM where he was responsible for their small and middle market buyouts, special situations and co-investments and was a member of the private equity executive committee and investment committee. Prior to WestAM, Mr. Oberholtzer was a Managing Director with Forstmann-Leff International (“FLI”) and a Director at Jefferies Group, where he was involved in product structure and fund management in equities and listed derivatives. His investment experience includes Chase Manhattan Bank, Dominick & Dominick and E.F. Hutton. Mr. Oberholtzer has served as the president of two private financial services companies and was active in a successful family business for several years.